In a different case report, a patient with antisynthetase syndrome and refractory myositis and interstitial lung disease showed improvement in muscle and pulmonary function after CD19 CAR T cell therapy [95] and a patient with juvenile dermatomyositis reached a dramatic response after this treatment modality [96]. Here, CD19 is linked to myositis disease.